Hope Rugo
机构: Professor of Medicine, University of California San Francisco
每年引用次数
引用次数
引用: 93,526
H-指数: 135
I10-指数 : 616
出版物: 1,804
NCCN Practice Guidelines for Cancer-Related Fatigue.
A. Peterman , P. Kaldor , J. Donnelly , C. Escalante
Oncology 14 151 -161
668
2000
137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
E. Ciruelos , L. Ryvo , P.F. Conte , D. Juric
Annals of Oncology 27
2016
136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC
A. Schneeweiss , L. Emens , J. de la Haba-Rodriguez , S. Adams
Annals of Oncology 27
2016
Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
J. O’Shaughnessy , T. Yamashita , A. Zimmermann , H. Rugo
The Breast 56
2021
P01.02 Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study
H. Borghaei , J. Mazieres , A. D'Amelio , S. Popat
Journal of Thoracic Oncology 16 ( 3)
2021
A feasibility study of an aromatase inhibitor (AI), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
T. A. Traina , M. N. Dickler , J. F. Caravelli , B. M. Yeh
Journal of Clinical Oncology 23 796 -796
6
2005
Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)
I. E. Krop , H. A. Burris , H. Rugo , J. O'Shaughnessy
Journal of Clinical Oncology 27 1003 -1003
8
2009
A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results
C. L. Vogel , H. A. Burris , S. Limentani , R. Borson
Journal of Clinical Oncology 27 1017 -1017
62
2009
Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088
E. Mayer , J. Baurain , J. Sparano , L. Strauss
Journal of Clinical Oncology 27 1011 -1011
24
2009
Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy
P. N. Munster , M. Lacevic , S. Thomas , C. Christian
Journal of Clinical Oncology 27 1075 -1075
16
2009
registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC)
D. Tripathy , P. Kaufman , A. Brufsky , M. Mayer
Journal of Clinical Oncology 27 1057 -1057
1
2009
Number needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC)
N. Dhillon , S. Kaura , G. Dranitsaris , H. Rugo
Journal of Clinical Oncology 27 581 -581
2
2009
Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer
M. N. Dickler , H. L. McArthur , B. Nulsen , S. Patil
Journal of Clinical Oncology 27 602 -602
1
2009
P182 NEPA, a new combination antiemetic, exhibits sustained efficacy over repeated chemotherapy cycles
M. Aapro , H. Rugo , G. Rizzi
The Breast 24
2015
2049 POSTER Adjuvant therapy for early stage breast cancer (EBC): distant disease-free survival (DDFS) as a predictor of overall survival (OS)
H. Rugo
Ejc Supplements 5 ( 4) 199
2007
2103 ORAL A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)
S. Chan , A. Stopeck , A.A. Joy , S. Verma
Ejc Supplements 5 ( 4) 214
21
2007
Zoledronic acid (ZA) as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells (DTC) in bone marrow (BM)
A. Lin , J. Park , M. Melisko , A. Goga
Ejc Supplements 6 ( 7) 120
17
2008
Preliminary evidence of an association between candidate channel genes and preoperative breast pain in women with breast cancer
D. Langford , B. McCann , C. Miaskowski , T. Koetters
The Journal of Pain 13 ( 4)
2012
Variations in inflammatory cytokine genes are associated with persistent severe breast pain after breast cancer surgery
K. Stephens , B. Cooper , D. Langford , T. Koetters
The Journal of Pain 14 ( 4)
2013
Identification of distinct subgroups of patients with arm pain following breast cancer surgery
C. Miaskowski , D. Langford , T. Koetters , C. West
The Journal of Pain 14 ( 4)
2013